Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

If You Invested $1,000 in Moderna Stock in January, This Is How Much You'd Have Now

By Joe Tenebruso - Dec 31, 2020 at 1:08PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The vaccine maker is helping to battle COVID-19 -- and it has been making its investors rich in the process.

Moderna ( MRNA -2.82% ) has had quite a year.

Developing a vaccine that could help to bring about the end of a pandemic apparently has a way of boosting a company's stock price. So how much good fortune has Moderna produced for its shareholders in 2020? Let's review.

A person is holding out a stack of $100 bills.

Image source: Getty Images.

Moderna delivered a much-needed ray of hope to the world in November, when a phase 3 clinical trial showed its coronavirus vaccine candidate, mRNA-1273, to be 94.1% effective against COVID-19 -- and as much as 100% effective at preventing severe cases of the disease. 

In addition, Moderna's vaccine was found to be generally safe and well-tolerated, with no serious safety concerns identified among the study's more than 30,000 participants.

The world cheered. And investors reacted by bidding up Moderna's shares, which were already up sharply year to date at that point based on the prior progress of its coronavirus vaccine development efforts.

All told, as of 11:45 a.m. EST on Dec. 31, Moderna's stock price is up 446% in 2020. So, for every $1,000 you invested in Moderna back in January, you'd have nearly $5,500 today. 

Yet even more gains may be in store for Moderna investors in 2021. The biotech company plans to use the profits it earns from sales of mRNA-1273 to fund the development of new vaccines for other diseases. Should one or more of them prove safe and effective, Moderna -- and its shareholders -- could have more great years to come.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$301.86 (-2.82%) $-8.75

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
635%
 
S&P 500 Returns
141%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/02/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.